Nanoradiopharmaceuticals Based on Alpha Emitters: Recent Developments for Medical Applications

Area of Science:

• Nuclear Medicine
• Nanotechnology
• Radiochemistry

Background:

• Nanotechnology offers novel therapeutic strategies in nuclear medicine, especially for cancer treatment.
• Targeted alpha-particle therapy (TAT) using nanoparticles shows promise for localized cell killing due to high energy transfer and short ranges.
• Current radiolabeling methods are suboptimal for alpha emitters because alpha decay's recoil energy disrupts chemical bonds.

Purpose of the Study:

• To review the physics, radiobiology, and production of alpha emitters for targeted alpha-particle therapy.
• To highlight challenges associated with alpha emitters, focusing on managing recoil energy.
• To summarize recent in vitro and in vivo preclinical investigations of alpha-particle therapy delivered by various nanosystems.

Main Methods:

• Review of literature on alpha emitter physics, radiobiology, and production.
• Analysis of strategies for managing recoil energy in radiolabeling.
• Summary of preclinical studies using nanosystems (inorganic nanoparticles, liposomes, polymersomes, carbon-based systems) for alpha-particle therapy.

Main Results:

• Alpha-particle therapy, when delivered via nanoparticles, presents a potent strategy for localized cancer cell killing.
• Effective management of recoil energy is critical for stable radiolabeling and therapeutic efficacy.
• Diverse nanosystems demonstrate potential for delivering alpha emitters in preclinical settings.

Conclusions:

• Nanotechnology-based targeted alpha-particle therapy is a promising approach for cancer treatment.
• Addressing recoil energy challenges through innovative radiolabeling is essential for clinical translation.
• Further preclinical investigations of various nanosystems are warranted to optimize alpha-particle therapy delivery.